SAShehbaz Ali
Shehbaz Ali
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shehbaz Ali has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Qaseem
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
3 shared publications - Abdul Haseeb Hasan
Department of Medicine King Edward Medical University Lahore Pakistan
2 shared publications - Imad Khan
Department of Medicine, Northwest School of Medicine, Peshawar, Pakistan
1 shared publication - Mian Sajjad Ali
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publication - Naveed Ahmad
Khyber Medical College, Peshawar, Pakistan
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4754-4755
Antiphospholipid syndrome-associated myocarditis: role of 18F-FDG PET/CT in differentiation from immune-mediated or viral etiologies
Was not provided for this article.
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4754-4755
Open AccessAntiphospholipid syndrome-associated myocarditis: role of 18F-FDG PET/CT in differentiation from immune-mediated or viral etiologies
Was not provided for this article.
- Open Access
- 21 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4759-4760
From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Was not provided for this article.
- 21 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4759-4760
Open AccessFrom pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Was not provided for this article.
- Open Access
- 16 May 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (5) , e70294
Neprilysin and Hypertension: Cause, Consequence, or Marker?
- 16 May 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (5) , e70294
Open AccessNeprilysin and Hypertension: Cause, Consequence, or Marker?